 ACHONDROPLASIA
|
ADENOCARCINOMA OF LUNG, RESP
|
ADENOCARCINOMA OF LUNG, SOMATIC
|
ASTROCYTOMA, LOW-GRADE,
|
BEARE-STEVENSON CUTIS GYRATA SYNDROME
|
BLADDER CANCER, SOMATIC
|
BREAST CANCER, SUSCEPTIBILITY TO
|
CAMPTODACTYLY TALL STATURE AND HEARING LOSS SYNDROME (CATSHL SYNDROME)
|
CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS S
|
CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME
|
CARDIOFACIOCUTANEOUS SYNDROME
|
CARDIOFACIOCUTANEOUS SYNDROME (CFC SYNDROME)
|
CATARACT CORTICAL AGE-RELATED TYPE 2 (ARCC2)
|
CATARACT, AGE-RELATED CORTICAL, 2
|
CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH HIRSCHSPRUNG DISEASE
|
CEREBRAL INFARCTION, SUSCEPTIBILITY TO
|
CHRONIC MYELOID LEUKEMIA, RESISTANT TO IMATINIB
|
COFFIN-LOWRY SYNDROME
|
COFFIN-LOWRY SYNDROME (CLS)
|
COLON CANCER, SOMATIC
|
COLORECTAL CANCER (CRC)
|
COLORECTAL CANCER, SOMATIC
|
CONGENITAL INSENSITIVITY TO PAIN WITH ANHIDROSIS (CIPA)
|
CONGENITAL STATIONARY NIGHT BLINDNESS OGUCHI TYPE 2 (CSNBO2)
|
CROUZON SYNDROME
|
CROUZON SYNDROME (CS)
|
CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS
|
CUTANEOUS MALIGNANT MELANOMA TYPE 3 (CMM3)
|
DIABETES MELLITUS, GESTATIONAL
|
DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS
|
DIABETES MELLITUS, NONINSULIN-DEPENDENT
|
DIABETES MELLITUS, PERMANENT NEONATAL
|
DIABETES MELLITUS, TYPE II
|
DOMINANTLY INHERITED VENOUS MALFORMATIONS (VMCM)
|
ENDOCRINE-CEREBROOSTEODYSPLASIA
|
ENDOCRINE-CEREBROOSTEODYSPLASIA (ECO)
|
ENDOMETRIAL CANCER, SOMATIC
|
EPILEPTIC ENCEPHALOPATHY EARLY INFANTILE TYPE 2 (EIEE2)
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
FAMILIAL SCAPHOCEPHALY SYNDROME (FSPC)
|
FG SYNDROME TYPE 4 (FGS4)
|
GASTRIC CANCER, SOMATIC
|
GLIOBLASTOMA, SOMATIC
|
GLYCOGEN STORAGE DISEASE IXC
|
GLYCOGEN STORAGE DISEASE TYPE 9C (GSD9C)
|
HEMANGIOMA, CAPILLARY INFANTILE, SOMATIC
|
HEPATOCELLULAR CARCINOMA (HCC)
|
HEREDITARY PAPILLARY RENAL CARCINOMA (HPRC)
|
HIRSCHSPRUNG DISEASE (HSCR)
|
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1
|
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3
|
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5
|
HYPOCHONDROPLASIA
|
HYPOCHONDROPLASIA (HCH)
|
HYPOGONADOTROPIC HYPOGONADISM
|
IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM (IHH)
|
INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS
|
INSULIN RESISTANCE
|
INSULIN RESISTANCE (INS RESISTANCE)
|
INSULIN-RESISTANT DIABETES MELLITUS WITH ACANTHOSIS NIGRICANS TYPE A (IRAN TYPE A)
|
KALLMANN SYNDROME 2
|
KALLMANN SYNDROME 2 WITH BIMANUAL SYNKINESIA
|
KALLMANN SYNDROME 2 WITH CLEFT PALATE
|
KALLMANN SYNDROME TYPE 2 (KAL2)
|
LACRIMO-AURICULO-DENTO-DIGITAL SYNDROME (LADDS)
|
LADD SYNDROME
|
LEOPARD SYNDROME 2
|
LEPRECHAUNISM
|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
LUNG CANCER
|
LYMPHEDEMA, HEREDITARY, I
|
LYMPHEDEMA, HEREDITARY, IA
|
LYMPHOMA, NON-HODGKIN
|
MALE INFERTILITY WITH LARGE-HEADED, MULTIFLAGELLAR, POLYPLOID SPERMATOZOA
|
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE II
|
MEDULLARY THYROID CARCINOMA (MTC)
|
MELANOMA, CUTANEOUS MALIGNANT, 3
|
MELANOMA, MALIGNANT, SOMATIC
|
MELANOMA, SPORADIC MALIGNANT
|
MENTAL RETARDATION X-LINKED CASK-RELATED (MRXCASK)
|
MENTAL RETARDATION X-LINKED TYPE 30 (MRX30)
|
MENTAL RETARDATION, X-LINKED 19
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB
|
MULTIPLE MYELOMA, SOMATIC
|
MULTIPLE NEOPLASIA TYPE 2B (MEN2B)
|
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
|
NEVUS, EPIDERMAL
|
NON-HODGKIN LYMPHOMA (NHL)
|
NONINSULIN-DEPENDENT DIABETES MELLITUS (NIDDM)
|
NONSMALL CELL LUNG CANCER, RESISTANCE TO TYROSINE KINASE INHIBITOR IN
|
NONSMALL CELL LUNG CANCER, RESPONSE TO TYROSINE KINASE INHIBITOR IN, SOMATIC
|
NONSMALL CELL LUNG CANCER, SOMATIC
|
NOONAN SYNDROME 5
|
NOONAN SYNDROME TYPE 5 (NS5)
|
NULL
|
OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY
|
OGUCHI DISEASE 2
|
OVARIAN CANCER (OC)
|
OVARIAN CANCER, SOMATIC
|
PARKINSON DISEASE 8, AUTOSOMAL DOMINANT
|
PARKINSON DISEASE TYPE 8 (PARK8)
|
PEUTZ-JEGHERS SYNDROME
|
PEUTZ-JEGHERS SYNDROME (PJS)
|
PFEIFFER SYNDROME
|
PFEIFFER SYNDROME (PS)
|
PHEOCHROMOCYTOMA
|
PHEOCHROMOCYTOMA, SOMATIC
|
POLYCYSTIC KIDNEY DISEASE 2
|
PROSTATE CANCER (PC)
|
PROSTATE CANCER, PROGRESSION AND METASTASIS OF
|
PROSTATE CANCER, SOMATIC
|
RABSON-MENDENHALL SYNDROME (RMS)
|
RECESSIVE ROBINOW SYNDROME (RRS)
|
RENAL ADYSPLASIA
|
RENAL AGENESIS
|
RETINITIS PIGMENTOSA (RP)
|
SADDAN DYSPLASIA
|
SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION
|
SCID DUE TO ZAP70 DEFICIENCY
|
SELECTIVE T-CELL DEFECT (STD)
|
SELECTIVE T-CELL DEFECT, IMMUNODEFICIENCY DUE TO
|
SEVERE COMBINED IMMUNODEFICIENCY AUTOSOMAL RECESSIVE T-CELL-NEGATIVE/B-CELL-POSITIVE/NK-CELL-NEGATIVE (T(-)B(+)NK(-) SCI
|
SPERMATOCYTIC SEMINOMA,
|
SPERMATOCYTIC SEMINOMA, SOMATIC
|
SPINOCEREBELLAR ATAXIA 14
|
TESTICULAR TUMOR, SOMATIC
|
TESTICULAR TUMORS (TEST)
|
THANATOPHORIC DYSPLASIA TYPE (TD)
|
THANATOPHORIC DYSPLASIA, TYPE I
|
THANATOPHORIC DYSPLASIA, TYPE II
|
THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 2
|
THYROID CARCINOMA, FAMILIAL MEDULLARY
|
THYROID CARCINOMA, FOLLICULAR, SOMATIC
|
THYROID CARCINOMA, PAPILLARY, SOMATIC
|
THYROID CARCINOMA, SPORADIC MEDULLARY
|
N-terminal catalytic domain of the Protein Serine/Threonine Kinase, 90 kDa ribosomal protein S6 kinase. Serine/Threonine Kinases (STKs), 90 kDa ribosomal protein S6 kinase (RSK) subfamily, N-terminal catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The RSK subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. RSKs contain an N-terminal kinase domain (NTD) from the AGC family and a C-terminal kinase domain (CTD) from the CAMK family. They are activated by signaling inputs from extracellular regulated kinase (ERK) and phosphoinositide dependent kinase 1 (PDK1). ERK phosphorylates and activates the CTD of RSK, serving as a docking site for PDK1, which phosphorylates and activates the NTD, which in turn phosphorylates all known RSK substrates. RSKs act as downstream effectors of mitogen-activated protein kinase (MAPK) and play key roles in mitogen-activated cell growth, differentiation, and survival. Mammals possess four RSK isoforms (RSK1-4) from distinct genes. RSK proteins are also referred to as MAP kinase-activated protein kinases (MAPKAPKs), p90-RSKs, or p90S6Ks.
No pairwise interactions are available for this conserved domain.
